In the assessment of 12-month price targets, analysts unveil insights for Vanda Pharma, presenting an average target of $18.4 ...
H.C. Wainwright raised the firm’s price target on Vanda Pharmaceuticals (VNDA) to $20 from $18 and keeps a Buy rating on the shares. The firm ...
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), a biopharmaceutical company focused on developing and commercializing therapies for unmet medical needs, has been navigating a complex landscape of ...
Vanda Pharmaceuticals (NASDAQ:VNDA – Free Report) had its price target upped by HC Wainwright from $18.00 to $20.00 in a research note issued to investors on Tuesday morning,Benzinga reports. HC ...
Vanda Pharmaceuticals Inc (VNDA) reports strong Fanapt sales growth and strategic initiatives, despite facing increased ...
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Vanda (VNDA – Research Report) on February 14 and set a price target of ...
Q4 2024 Earnings Call Transcript February 13, 2025 Vanda Pharmaceuticals Inc. beats earnings expectations. Reported EPS is ...
Vanda Pharmaceuticals emphasized its strategic focus on expanding its psychiatry portfolio through the launches of Fanapt in bipolar I disorder and the anticipated approvals for Bysanti and Fanapt ...
WASHINGTON (AP) — WASHINGTON (AP) — Vanda Pharmaceuticals Inc. (VNDA) on Thursday reported a loss of $4.9 million in its fourth quarter. On a per-share basis, the Washington-based company said it had ...
Hello, and thank you for standing by. At this time, I would like to welcome you to the Q4 2024 Vanda Pharmaceuticals, Inc. Earnings Conference Call. [Operator Instructions] I would now like to ...
WASHINGTON (AP) — WASHINGTON (AP) — Vanda Pharmaceuticals Inc. (VNDA) on Thursday reported a loss of $4.9 million in its fourth quarter. On a per-share basis, the Washington-based company said ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results